Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA; Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA; Dallas Veterans Administration North Texas Health System, Dallas, TX, USA.
Department of Applied Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
J Clin Lipidol. 2020 Jul-Aug;14(4):425-430. doi: 10.1016/j.jacl.2020.04.007. Epub 2020 Apr 25.
Non-high-density lipoprotein cholesterol (non-HDL-C) includes atherogenic cholesterol and low-density lipoproteins (LDL) and triglyceride-rich lipoproteins. Patients with diabetes frequently have elevations in non-HDL-C.
This study examines temporal trends in the levels of non-HDL-C in free-living subjects with diabetes but a negative history of atherosclerotic cardiovascular disease.
National Health and Nutrition Examination Surveys conducted between 1999 and 2016 had data from 3,219 adults (aged 40-75 years) with diabetes. Temporal trends in changes in the distribution of total cholesterol, non-HDL-C, LDL cholesterol (LDL-C), and HDL-C were evaluated. Data were weighted to account for complex survey design.
Significant decreases were observed in non-HDL-C (20.1%; P < .0001) and total cholesterol (16.1%; P < .0001) levels between 1999 and 2016. No significant changes were noted in HDL-C levels. LDL-C was reduced by 29.6% in a subset of subjects. The reduction in non-HDL-C and LDL-C occurred simultaneously, with an increase of 4.4% of subjects per year taking cholesterol-lowering drugs and statins. In contrast, the fraction of subjects taking antihypertensives or hypoglycemia agents rose at a rate of 2.2% per year. There was also a significant trend for increases in weight gain (P ≤ .013).
In subjects with diabetes, non-HDL-C levels have declined over time in parallel with reported increases in cholesterol-lowering drugs. Nonetheless, treatment targets for lipids in subjects with diabetes lag behind current recommendations. Reported intakes for antihypertensive agents and hypoglycemia agents were relatively high throughout the period of study, with little change over time. However, there was a trend for weight increase in diabetic subjects, which may offset some of the benefits of pharmacotherapy.
非高密度脂蛋白胆固醇(non-HDL-C)包括致动脉粥样硬化胆固醇和低密度脂蛋白(LDL)以及富含三酸甘油脂的脂蛋白。患有糖尿病的患者常伴有非高密度脂蛋白胆固醇升高。
本研究旨在检测既往无动脉粥样硬化性心血管疾病史的糖尿病患者中非高密度脂蛋白胆固醇水平的时间变化趋势。
在 1999 年至 2016 年进行的全国健康与营养调查中,有 3219 名年龄在 40-75 岁的糖尿病患者纳入本研究。评估了总胆固醇、非高密度脂蛋白胆固醇、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)分布变化的时间趋势。对数据进行加权以考虑复杂的调查设计。
1999 年至 2016 年间,非高密度脂蛋白胆固醇(20.1%;P<0.0001)和总胆固醇(16.1%;P<0.0001)水平显著下降。HDL-C 水平无显著变化。在部分患者中,LDL-C 降低了 29.6%。与此同时,每年服用降脂药物和他汀类药物的患者增加了 4.4%,非高密度脂蛋白胆固醇和 LDL-C 随之降低。相比之下,每年服用抗高血压药物或降血糖药物的患者比例以 2.2%的速度增加。体重增加也呈显著趋势(P≤0.013)。
在糖尿病患者中,非高密度脂蛋白胆固醇水平随时间推移呈下降趋势,同时降脂药物的使用也有所增加。然而,糖尿病患者的血脂治疗目标仍落后于目前的建议。在整个研究期间,报告的抗高血压药物和降血糖药物的摄入量相对较高,且随时间变化不大。然而,糖尿病患者的体重呈增加趋势,这可能抵消了一些药物治疗的益处。